What is the current stock price of MannKind Corporation (MNKD)?

As of the latest market data, MannKind Corporation (MNKD) is trading at $2.57. The stock has seen a gain of 0.39% today.

Does MannKind Corporation (MNKD) pay a dividend?

Based on current data, MannKind Corporation does not have a confirmed active dividend policy.

What is the market cap of MannKind Corporation?

The current market capitalization of MannKind Corporation (MNKD) is approximately unavailable.

MNKD

MannKind Corporation·Healthcare

2.57

0.391%(+0.01)

Market Closed

2.65

3.113%(+0.08)

After Hours

Last Updated: — ET

52W L: $2.2352W H: $6.51

MNKD NEWS

defenseworld.net

Mar 12

MannKind (NASDAQ:MNKD) Shares Gap Up After Insider Buying Activity

MannKind Corporation (NASDAQ: MNKD - Get Free Report) gapped up prior to trading on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $2.61, but opened at $2.81. MannKind shares last traded at $2.7950, with a volume of 2,318,445 shares. Specifically, CEO Michael Castagna bought 100,000 shares of the

seekingalpha.com

Mar 11

MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

globenewswire.com

Mar 9

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD) PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

globenewswire.com

Mar 5

MannKind Announces Settlement of Convertible Senior Notes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock.

globenewswire.com

Mar 4

MannKind to Participate in Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

defenseworld.net

Mar 3

MannKind (NASDAQ:MNKD) Stock Price Down 6.6% on Analyst Downgrade

MannKind Corporation (NASDAQ: MNKD - Get Free Report) traded down 6.6% during mid-day trading on Monday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The company traded as low as $3.03 and last traded at $3.0650. 1,435,401 shares changed hands during trading, a decline of 72% from the average

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Sector

Healthcare

Industry

Biotechnology

Employees

403

IPO Date

2004-07-28

Beta

1.04

Websitewww.mannkindcorp.com↗